Ovarian cancer is the abnormal cell growth in the ovaries or fallopian tubes. These cells multiply quickly and invade the surrounding healthy tissues. According to World Cancer Research Fund International, ovarian cancer is the eighth most common cancer in women across the globe. There are several ovarian cancer emerging drugs under clinical trials intended to develop effective treatment alternatives.
The Ovarian Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights for ongoing ovarian cancer clinical trials. It covers various aspects related to the details of ovarian cancer drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on ovarian cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing ovarian cancer pipeline development activities are covered. Moreover, ovarian cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Ovarian cancer is when abnormal cells in the ovary start to grow in an uncontrolled manner and eventually lead to tumour formation. These cancer cells can start to grow into the surrounding healthy tissues and spread to other parts of the body as well. According to the American Cancer Society, approximately 19,680 women are expected to be diagnosed with ovarian cancer in 2024, and it is estimated that approximately 12,740 women will die from the condition.
The symptoms of ovarian cancer include abdominal bloating or swelling, discomfort in the pelvic area, feeling full quickly when eating, weight loss, back pain, fatigue, and constipation among others. The ovarian cancer treatment depends on the stage of cancer and the patient's age. The standard treatment includes surgery, chemotherapy, targeted therapy, immunotherapy, and hormone therapy, among others. In 2022, the United States Food and Drug Administration (FDA) provided accelerated ap proval to mirvetuximab soravtansine-gynx (Elahere), the first antibody-drug conjugate for platinum-resistant ovarian cancer.
Multiple NCI-supported research programs are being conducted to develop innovative treatments for ovarian cancer. For instance, the Ovarian Specialized Programs of Research Excellence (SPOREs ) promote cancer research. This organization works to improve treatment approaches for ovarian cancer.
Merck is developing an ovarian cancer emerging drug through its flagship drug Keytruda (pembrolizumab), in combination with carboplatin/paclitaxel chemotherapy. The trial is currently under phase III.
The ovarian cancer report assessment covers the pathophysiology and epidemiology of ovarian cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment of ovarian cancer in detail. Genelux Corp is investigating olvimulogene nanivacirepvec, currently under phase III trial. The study evaluates the safety and efficacy of platinum-doublet plus bevacizumab compared to platinum-doublet plus bevacizumab.
This section of the report covers the analysis of ovarian cancer drug candidates based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Route of Administration
EMR’s ovarian cancer therapeutic assessment report covers 50+ drug analyses based on the route of administration.
The ovarian cancer pipeline analysis covers phase I, phase II, phase III, phase IV, and early phase drugs for ovarian cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover major share of the total ovarian cancer clinical trials conducted.
AstraZeneca is conducting phase II clinical trial for the drug ola parib to evaluate its efficacy in combination with paclitaxel.
The route of administration categories covered under ovarian cancer pipeline landscape include oral, parenteral and others. The report offers a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route accounted for a major share of ovarian cancer clinical trials.
The EMR ovarian cancer report insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in clinical trials for ovarian cancer.
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for ovarian cancer. Moreover, it includes product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
Currently, under phase II, the drug is sponsored by Sanofi. The purpose of the study is to assess the safety and efficacy of the first line treatment for advanced epithelial ovarian cancer.
Liposomal Doxorubicin developed by AstraZeneca is currently under phase II. The purpose of the study...
Paclitaxel, developed by Boehringer Ingelheim is presently under phase II. The study is being conduc...
The study is assessing the safety and efficacy MEDI4736 in combination with Olaparib vs MEDI4736 in ...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Global Cancer Supportive Care Drugs Market
Global Ovarian Cancer Diagnostics And Therapeutics Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Treatment Type |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Datasheet
USD 2,199
USD 1,899
tax inclusive*
Single User License
One User
USD 2,749
USD 2,299
tax inclusive*
Five User License
Five Users
USD 3,849
USD 3,299
tax inclusive*
Corporate License
Unlimited Users
USD 4,949
USD 4,199
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share